Liminal BioSciences Inc.: Liminal BioSciences Announces Termination of Legacy CDMO Contract

Termination results in anticipated cash savings of $33.1 millionRemoves last of legacy contracts associated with former plasma-derived therapeutics businessLAVAL, QC and CAMBRIDGE, ENGLAND,

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Canada ,Canadian ,Kaitlin Gallagher ,Bruce Pritchard ,Shrinal Inamdar ,Exchange Commission ,Master Services Agreement ,Prnewswire Liminal Biosciences Inc ,Securities Exchange ,Liminal Biosciences Inc ,Nasdaq ,Termination Agreement ,Liminal Biosciences ,Chief Executive Officer ,Securities Act ,Securities Exchange Act ,Liminal Bioscience ,Nasdaq Listing Rules ,Canadian Securities Administrators ,Annual Report ,Investor Relations ,Media Contact ,Liminal ,Iosciences ,Nnounces ,Termination ,Legacy ,Dmo ,Contract ,